GlassScriptPhysician profile
Elliot J Gruen
NPI 1295760106
$7,471.93
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,202 · 2020: $1,777 · 2021: $2,372 · 2022: $1,120.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,085.17 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $1,067.75 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $916.03 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $899.48 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $843.86 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $808.02 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $373.57 | 2019-2021 | |
| Lundbeck LLC | $358.76 | 2019-2022 | |
| Eisai INC. | $318.91 | 2020-2022 | |
| Shire North American Group INC | $203.45 | 2019 | |
| Abbvie INC. | $169.41 | 2021-2022 | |
| Allergan, INC. | $150.21 | 2019-2020 | |
| Alkermes, INC. | $141.06 | 2021 | |
| Neos Therapeutics, LP | $46.38 | 2019 | |
| Jazz Pharmaceuticals INC. | $42.39 | 2020-2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $34.61 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $12.87 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elliot Gruen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.